J McLaughlin

1.6k total citations
14 papers, 1.3k citations indexed

About

J McLaughlin is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, J McLaughlin has authored 14 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 9 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in J McLaughlin's work include Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Protein Degradation and Inhibitors (4 papers). J McLaughlin is often cited by papers focused on Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Protein Degradation and Inhibitors (4 papers). J McLaughlin collaborates with scholars based in United States, Switzerland and Canada. J McLaughlin's co-authors include Owen N. Witte, Naomi Rosenberg, Michelle A. Kelliher, Michael Paskind, Anne‐Marie Mes‐Masson, George Q. Daley, Daniel Afar, Martine F. Roussel, Charles J. Sherr and Kevan M. Shokat and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Molecular and Cellular Biology and Leukemia.

In The Last Decade

J McLaughlin

14 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J McLaughlin United States	11	1.1k	778	346	323	248	14	1.3k
G Grosveld Netherlands	8	1.1k 1.1×	761 1.0×	441 1.3×	293 0.9×	289 1.2×	13	1.5k
JV Melo United Kingdom	11	849 0.8×	637 0.8×	242 0.7×	275 0.9×	240 1.0×	17	1.1k
Eric P. Stoffregen United States	15	1.8k 1.7×	1.4k 1.8×	433 1.3×	1.0k 3.2×	232 0.9×	19	2.2k
J V Melo United Kingdom	16	553 0.5×	644 0.8×	280 0.8×	184 0.6×	126 0.5×	26	1.1k
Stephane Wong United States	11	495 0.5×	339 0.4×	349 1.0×	179 0.6×	86 0.3×	15	802
R B Arlinghaus United States	11	469 0.4×	370 0.5×	204 0.6×	185 0.6×	90 0.4×	17	725
Melissa Holtz United States	9	904 0.8×	610 0.8×	318 0.9×	405 1.3×	74 0.3×	11	1.1k
Marie Havlik United States	13	527 0.5×	354 0.5×	580 1.7×	127 0.4×	77 0.3×	15	1.1k
G Q Daley United States	5	513 0.5×	345 0.4×	194 0.6×	166 0.5×	88 0.4×	5	641
Robert C. Quackenbush United States	7	501 0.5×	311 0.4×	333 1.0×	133 0.4×	78 0.3×	7	913

Countries citing papers authored by J McLaughlin

Since Specialization

Citations

This map shows the geographic impact of J McLaughlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J McLaughlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J McLaughlin more than expected).

Fields of papers citing papers by J McLaughlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J McLaughlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J McLaughlin. The network helps show where J McLaughlin may publish in the future.

Co-authorship network of co-authors of J McLaughlin

This figure shows the co-authorship network connecting the top 25 collaborators of J McLaughlin. A scholar is included among the top collaborators of J McLaughlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J McLaughlin. J McLaughlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Ting, Pamela Y., J McLaughlin, Dongrui Cheng, et al.. (2010). ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1. Leukemia. 25(2). 290–300. 15 indexed citations

McLaughlin, J, et al.. (2004). Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proceedings of the National Academy of Sciences. 101(50). 17456–17461. 57 indexed citations

Mahlmann, Stefan, et al.. (1998). Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection. Leukemia. 12(12). 1858–1865. 9 indexed citations

Doane, Kathleen J., et al.. (1996). Spatial and Temporal Variations in Extracellular Matrix of Periocular and Corneal Regions During Corneal Stromal Development. Experimental Eye Research. 62(3). 285–292. 27 indexed citations

Afar, Daniel, J McLaughlin, Charles J. Sherr, Owen N. Witte, & Martine F. Roussel. (1995). Signaling by ABL oncogenes through cyclin D1.. Proceedings of the National Academy of Sciences. 92(21). 9540–9544. 71 indexed citations

Afar, Daniel, et al.. (1994). Genetic Approaches to Defining Signaling by the CML-associated Tyrosine Kinase BCR-ABL. Cold Spring Harbor Symposia on Quantitative Biology. 59(0). 589–594. 6 indexed citations

McLaughlin, J, Ann Marie Pendergast, Kalindi Parmar, et al.. (1993). Oncogenic activation of c-ABL by mutation within its last exon.. Molecular and Cellular Biology. 13(8). 4967–4975. 38 indexed citations

Kelliher, Michelle A., et al.. (1991). Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.. Molecular and Cellular Biology. 11(9). 4710–4716. 67 indexed citations

Gishizky, Mikhail L., J McLaughlin, Ann Marie Pendergast, & Owen N. Witte. (1991). The 5' non-coding region of the BCR/ABL oncogene augments its ability to stimulate the growth of immature lymphoid cells.. PubMed. 6(8). 1299–306. 2 indexed citations

10.

Kelliher, Michelle A., J McLaughlin, Owen N. Witte, & Naomi Rosenberg. (1990). Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.. Proceedings of the National Academy of Sciences. 87(17). 6649–6653. 426 indexed citations

11.

McLaughlin, J, et al.. (1989). Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.. Molecular and Cellular Biology. 9(5). 1866–1874. 129 indexed citations

12.

McLaughlin, J, et al.. (1987). In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.. Proceedings of the National Academy of Sciences. 84(18). 6558–6562. 320 indexed citations

13.

Konopka, James B., Susan Spierre Clark, J McLaughlin, et al.. (1986). Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients.. Proceedings of the National Academy of Sciences. 83(11). 4049–4052. 30 indexed citations

14.

Mes‐Masson, Anne‐Marie, J McLaughlin, George Q. Daley, Michael Paskind, & Owen N. Witte. (1986). Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome.. Proceedings of the National Academy of Sciences. 83(24). 9768–9772. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact